Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Crescent Biopharma	$15.06 +4.6%	$13.90	$10.83 ▼ $63.00	$281.52M	1.51	101,376 shs	44,912 shs
CDXS Codexis	$2.88 +2.1%	$2.77	$1.90 ▼ $6.08	$254.55M	2.54	1.21 million shs	1.22 million shs
SNSS Sunesis Pharmaceuticals		$3.53	$1.12 ▼ $11.30	$96.26M	2.27	4.33 million shs	1.20 million shs
XOMA XOMA Royalty	$34.20 +4.4%	$27.20	$18.35 ▼ $35.00	$395.87M	1	46,803 shs	111,643 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Crescent Biopharma	+4.58%	+9.21%	+14.26%	-98.04%	-98.04%
CDXS Codexis	+2.13%	-4.32%	-13.51%	+20.00%	-4.00%
SNSS Sunesis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
XOMA XOMA Royalty	+4.43%	+9.02%	+31.89%	+37.63%	+17.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBIO Crescent Biopharma	3.8258 of 5 stars	4.7	0.0	0.0	3.7	2.4	1.7	0.6
CDXS Codexis	3.5024 of 5 stars	3.3	2.0	0.0	2.5	1.7	1.7	0.6
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	4.2462 of 5 stars	3.3	4.0	0.0	3.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBIO Crescent Biopharma	3.40	Buy	$25.50	69.32% Upside
CDXS Codexis	2.50	Moderate Buy	$11.00	281.94% Upside
SNSS Sunesis Pharmaceuticals	0.00	N/A	N/A	N/A
XOMA XOMA Royalty	2.67	Moderate Buy	$69.50	103.22% Upside

Current Analyst Ratings Breakdown

Latest SNSS, XOMA, CDXS, and CBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XOMA XOMA Royalty	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	$6.92 per share	N/A
CDXS Codexis	$59.35M	4.38	N/A	N/A	$0.62 per share	4.65
SNSS Sunesis Pharmaceuticals	$2.07M	0.00	N/A	N/A	$1.42 per share	0.00
XOMA XOMA Royalty	$28.49M	14.51	N/A	N/A	$5.99 per share	5.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBIO Crescent Biopharma	-$37.88M	-$34.93	N/A	N/A	N/A	N/A	-106.06%	-86.60%	N/A
CDXS Codexis	-$65.28M	-$0.83	N/A	N/A	N/A	-113.67%	-105.83%	-46.06%	10/30/2025 (Estimated)
SNSS Sunesis Pharmaceuticals	-$23.33M	-$2.70	N/A	N/A	N/A	N/A	-179.05%	-72.27%	N/A
XOMA XOMA Royalty	-$13.82M	-$1.55	N/A	N/A	N/A	-27.57%	2.63%	0.97%	11/6/2025 (Estimated)

Latest SNSS, XOMA, CDXS, and CBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	CDXS Codexis	-$0.17	-$0.16	+$0.01	-$0.16	$14.18 million	$15.33 million
8/13/2025	Q2 2025	XOMA XOMA Royalty	-$0.12	$0.48	+$0.60	$0.44	$9.39 million	$13.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
CDXS Codexis	N/A	N/A	N/A	N/A	N/A
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBIO Crescent Biopharma	N/A	9.21	9.21
CDXS Codexis	0.71	5.82	5.70
SNSS Sunesis Pharmaceuticals	N/A	7.74	7.74
XOMA XOMA Royalty	1.41	4.88	4.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBIO Crescent Biopharma	75.19%
CDXS Codexis	78.54%
SNSS Sunesis Pharmaceuticals	28.41%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
CBIO Crescent Biopharma	4.00%
CDXS Codexis	1.90%
SNSS Sunesis Pharmaceuticals	4.22%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
CDXS Codexis	250	90.27 million	88.55 million	Optionable
SNSS Sunesis Pharmaceuticals	24	18.09 million	N/A	Optionable
XOMA XOMA Royalty	10	12.09 million	10.99 million	Optionable

SNSS, XOMA, CDXS, and CBIO Headlines

Recent News About These Companies

Xoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy Rating

August 22 at 6:10 AM | tipranks.com

Mural Oncology and XOMA Royalty Corporation Announce Definitive Agreement for Acquisition of Mural Oncology

August 20 at 9:31 AM | quiverquant.comQ

Mural Oncology to be acquired by XOMA unit for up to $2.24/share in cash

August 20 at 9:11 AM | seekingalpha.com

Mural Oncology Enters Definitive Agreement for Acquisition by XOMA Royalty Corporation in Cash Deal Valued at Approximately $36.2 Million

August 20 at 8:51 AM | quiverquant.comQ

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20 at 8:49 AM | globenewswire.com

Q3 EPS Estimates for XOMA Royalty Reduced by Leerink Partnrs

August 19, 2025 | marketbeat.com

Leerink Partnrs Expects Reduced Earnings for XOMA Royalty

August 19, 2025 | americanbankingnews.com

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

August 18, 2025 | zacks.com

Leerink Partnrs Raises Earnings Estimates for XOMA Royalty

August 17, 2025 | marketbeat.com

XOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at Zacks Research

August 17, 2025 | marketbeat.com

XOMA Royalty (NASDAQ:XOMA) Releases Earnings Results, Beats Estimates By $0.60 EPS

August 16, 2025 | marketbeat.com

XOMA Royalty Corporation Beat Analyst Profit Forecasts, And Analysts Have New Estimates

August 16, 2025 | finance.yahoo.com

LAVA Therapeutics Announces Acquisition by XOMA Corporation

August 14, 2025 | tipranks.com

Xoma Corp. Reports Strong Earnings Growth in 2025

August 14, 2025 | msn.com

LAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 Development

August 13, 2025 | quiverquant.comQ

Cautious Hold Rating on Xoma Amid Strategic Acquisitions and Uncertain Growth Outlook

August 13, 2025 | tipranks.com

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

August 13, 2025 | zacks.com

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025 | globenewswire.com

XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025 | finanznachrichten.de

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025 | finance.yahoo.com

XOMA Royalty (NASDAQ:XOMA) Upgraded to "Buy" at Wall Street Zen

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSS, XOMA, CDXS, and CBIO Company Descriptions

Crescent Biopharma NASDAQ:CBIO

$15.06 +0.66 (+4.58%)

As of 08/22/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Codexis NASDAQ:CDXS

$2.88 +0.06 (+2.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.87 -0.01 (-0.31%)

As of 08/22/2025 07:43 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Sunesis Pharmaceuticals NASDAQ:SNSS

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

XOMA Royalty NASDAQ:XOMA

$34.20 +1.45 (+4.43%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$34.30 +0.10 (+0.31%)

As of 08/22/2025 04:01 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time